OncoCyte, Wistar to Develop Gene Expression-based Lung Cancer Diagnostic | GenomeWeb

NEW YORK (GenomeWeb News) – BioTime subsidiary OncoCyte today announced that it will collaborate with the Wistar Institute on the development of a gene expression-based lung cancer test.

Under the agreement, OncoCyte scientists will analyze levels of tumor-associated proteins in blood samples from patients in an ongoing study conducted by Wistar. Scheduled to wrap up in mid-2014, two thirds of a planned total of 600 samples have already been collected in the study.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.